Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling
- 1 May 2020
- journal article
- research article
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 52 (6) , 612-619
Abstract
Myocardial hypertrophy is a major pathological and physiological process during heart failure. Glucagon-like peptide 1 (GLP-1) is a glucagon incretin hormone released from the gut endocrine L-cells that has protective effects on various cardiovascular diseases, including hypertension, atherosclerosis, and myocardial hypertrophy. However, the protective mechanisms of GLP-1 in myocardial hypertrophy remain unclear. Here, we showed that the GLP-1 agonist liraglutide and dipeptidyl peptidase 4 inhibitor alogliptin decreased heart weight and cardiac muscle cell volume in spontaneously hypertensive rats (SHR). In H9C2 cell hypertensive models induced by angiotensin II, GLP-1 treatment reduced myocardial cell volume, inhibited the expressions of atrial natriuretic peptide, brain/B-type natriuretic peptide, β-myosin heavy chain, RhoA, and ROCK2, and decreased MLC and MYPT1 phosphorylation. When H9C2 cells were treated with H89, a PKA inhibitor, the inhibitory effect of GLP-1 disappeared, while the inhibitory role was enhanced under the treatment of Y-27632, a ROCK2 inhibitor. These results suggested that GLP-1 might reverse myocardial hypertrophy through the PKA/RhoA/ROCK2 signaling pathway.Keywords
Funding Information
- Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (2015-110, 2015-287)
- Natural Science Foundation of Shanxi Province (201801D121202, 201701D121085)
- National Natural Science Foundation of China (31170748)
This publication has 43 references indexed in Scilit:
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent MechanismDiabetes, 2013
- Cell cycle regulation of Rho signaling pathwaysCell Cycle, 2012
- Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery diseaseHeart, 2011
- Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategiesPharmacology & Therapeutics, 2010
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular systemAmerican Journal of Physiology-Cell Physiology, 2007
- Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful ReperfusionCirculation, 2004
- Reactive Oxygen Species in the VasculatureHypertension, 2003
- Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture.Hypertension, 1987
- Vasoconstriction: A New Activity for Platelet-Derived Growth FactorScience, 1986